XML 28 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
EQUITY-BASED COMPENSATION PLANS
3 Months Ended
Sep. 28, 2014
EQUITY-BASED COMPENSATION PLANS

NOTE 3 — EQUITY-BASED COMPENSATION PLANS

The Company has stock plans that provide for grants of equity-based awards to eligible participants, including stock options and restricted stock units (“RSUs”), of Lam Research common stock (“Common Stock”). An option is a right to purchase Common Stock at a set price. An RSU award is an agreement to issue shares of Common Stock at the time of vesting. The Company’s options and RSU awards typically vest over a period of three years or less, although awards assumed in connection with the acquisition of Novellus Systems, Inc. (“Novellus”), have vesting terms up to four years. The Company also has an employee stock purchase plan that allows employees to purchase its Common Stock at a discount through payroll deductions.

 

The Company recognized the following equity-based compensation expense and related income tax benefit in the Condensed Consolidated Statements of Operations:

 

     Three Months Ended  
     September 28,
2014
     September 29,
2013
 
     (in millions)  

Equity-based compensation expense

   $ 32.0       $ 23.2   

Income tax benefit related to equity-based compensation expense

   $ 4.7       $ 3.9   

The estimated fair value of the Company’s stock-based awards, less expected forfeitures, is amortized over the awards’ vesting term on a straight-line basis.

Stock Options and RSUs

The Lam Research Corporation 2007 Stock Incentive Plan and 2011 Stock Incentive Plan (collectively the “Stock Plans”) provide for the grant of non-qualified equity-based awards to eligible employees, consultants and advisors, and non-employee directors of the Company and its subsidiaries. A summary of stock plan transactions is as follows:

 

     Options Outstanding      Restricted Stock Units
Outstanding
 
     Number of
Shares
    Weighted-
Average
Exercise
Price
     Number of
Shares
    Weighted-
Average
Fair
Market
Value at
Grant
 

June 29, 2014

     1,331,886      $ 32.20         5,635,469      $ 45.83   

Granted

     —        $ —           67,439      $ 65.92   

Exercised

     (165,696   $ 27.81         N/A        N/A   

Cancelled

     (7,452   $ 29.86         (57,295   $ 44.54   

Vested restricted stock

     N/A        N/A         (387,148   $ 41.90   
  

 

 

      

 

 

   

September 28, 2014

     1,158,738      $ 32.84         5,258,465      $ 46.39   
  

 

 

      

 

 

   

As of September 28, 2014, there was $3.4 million of total unrecognized compensation cost related to unvested stock options granted and outstanding; that cost is expected to be recognized over a weighted-average remaining vesting period of 1.5 years. As of September 28, 2014, there was $154.2 million of total unrecognized compensation expense related to unvested RSUs granted; that expense is expected to be recognized over a weighted-average remaining period of 1.8 years.

ESPP

The 1999 Employee Stock Purchase Plan, as amended and restated (the “1999 ESPP”), allows employees to designate a portion of their base compensation to be withheld through payroll deductions and used to purchase Common Stock at a purchase price per share equal to the lower of 85% of the fair market value of Common Stock on the first or last day of the applicable purchase period. Each offering period generally lasts up to 12 months and includes up to three interim purchase dates.

Purchase rights under the 1999 ESPP were valued using the Black-Scholes option valuation model and the following weighted-average assumptions for the three months ended September 28, 2014 and September 29, 2013:

 

     Three Months Ended  
     September 28,
2014
    September 29,
2013
 

Expected term (years)

     0.68        0.66   

Expected stock price volatility

     29.07     31.43

Risk-free interest rate

     0.07     0.11

Dividend Yield

     0.29     —     

As of September 28, 2014, there was $13.2 million of unrecognized compensation expense related to the 1999 ESPP, which is expected to be recognized over a remaining period of approximately 11 months.